

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV323766028US, in an envelope addressed to: -MS Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 3-30-04

Signature: [Signature]

(Richard Zimmermann)

13024/38628A
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

John McMICHAEL

Application No.: Not Yet Assigned
(Continuation of 10/233,498)

Group Art Unit: Not Yet Assigned

Filed: **March 30, 2004**

Examiner: Not Yet Assigned

For: METHODS FOR ALLEVIATING
SYMPTOMS ASSOCIATED WITH
NEUROPATHIC CONDITIONS
COMPRISING ADMINISTRATION OF LOW
LEVELS OF ANTIBODIES

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

All patents or publications identified in the attached form PTO/SB/08 are not supplied because they were previously cited by or submitted to the Office in a prior Application No. 10/233,498 filed August 19, 2002 and relied upon in this application for an earlier filing date under 35 U.S.C. 120.

A concise explanation of relevance of the items listed on form PTO/SB/08 is not given.


While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606
312/474-6300

By:



Jeffrey S. Sharp
Registration No. 31,879
Attorney for Applicant

March 30, 2004

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	March 30, 2004
				First Named Inventor	John McMichael
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	1	of	3	Attorney Docket Number	13024/38628A

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number-Kind Code ² (if known)		
	A1	4,384,993	05-24-1983	Sato et al.
	A2	4,692,331	09-08-1987	Uemura et al.
	A3	5,645,998	07-08-1997	Atkinson et al.
	A4	5,762,937	06-09-1998	Atkinson et al.
	A5	5,792,620	08-11-1998	Lernmark et al.
	A6	6,001,360	12-14-1999	Atkinson et al.
	A7	6,011,139	01-04-2000	Tobin et al.
	A8	6,025,176	02-15-2000	Lernmark et al.
	A9	6,187,309	02-13-2001	McMichael et al.
	A10	6,294,171	09-25-2001	McMichael et al.
	A11	6,300,089	10-09-2001	Atkinson et al.

FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Country
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)		
	B1	CA -2,232,834	03-27-1997	CA
	B2	WO 92/20811	11-26-1992	PCT
	B3	WO 97/10847	03-27-1997	PCT

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	Not Yet Assigned
				Filing Date	March 30, 2004
				First Named Inventor	John McMichael
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	2	of	3	Attorney Docket Number	13024/38628A

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s); publisher, city and/or country where published.	T ²
	C1	Blanas <i>et al.</i> , "Induction of Autoimmune Diabetes by Oral Administration of Autoantigen," <i>Science</i> , 274:1707-1709 (1996).	
	C2	Graves <i>et al.</i> , "Lack of Association Between Early Childhood Immunizations and β -Cell Autoimmunity," <i>Diabetes Care</i> , 22:1694-1697 (1999).	
	C3	Kaufman <i>et al.</i> , "Spontaneous Loss of T-Cell Tolerance to Glutamic Acid Decarboxylase in Murine Insulin-Dependent Diabetes," <i>Nature</i> , 366: 69-72(1993).	
	C4	Tian <i>et al.</i> , "Modulating Autoimmune Responses to GAD Inhibits Disease Progression and Prolongs Islet Graft Survival in Diabetes-Prone Mice," <i>Nat. Med.</i> , 2:1348-1353 (1996).	
	C5	Tisch <i>et al.</i> , "Immune Response to Glutamic Acid Decarboxylase Correlates with Insulinitis in Non-Obese Diabetic Mice," <i>Nature</i> , 366:72-75 (1993).	
	C6	Ramiya <i>et al.</i> , "Effect of Oral and Intravenous Insulin and Glutamic Acid Decarboxylase in NOD Mice," <i>Autoimmunity</i> , 26:139-151 (1997).	
	C7	Song <i>et al.</i> , "Human Insulin B Chain but not A Chain Decreases the Rate of Diabetes in BB Rats," <i>Diabetes Research and Clinical Practice</i> , 46:109-114 (1999).	
	C8	Asperger, "Die Psychopathologie des Coeliakakranken Kindes," <i>Ann. Pediatr.</i> , 197:346-351 (1961).	
	C9	Barker <i>et al.</i> , "A Role for Complement in the Rejection of Porcine Ventral Mesencephalic Xenografts in a Rat Model of Parkinson's Disease," <i>J. of Neuroscience</i> , 20:3415-3424 (2000).	
	C10	DiFiglia <i>et al.</i> , "Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain," <i>Science</i> , 277:1990-1993 (1998).	
	C11	Dirkx <i>et al.</i> , "Targeting of the 65-kDa Isoform of Glutamic Acid Decarboxylase to Intracellular Organelles is Mediated by Its Interaction with the NH ₂ -terminal Region of the 65-kDa Isoform of Glutamic Acid Decarboxylase," <i>J. Biol. Chem.</i> , 270:2241-2246 (1995).	
	C12	Fahn <i>et al.</i> , "Double-Blind Controlled Trial of Human Embryonic Dopaminergic Tissue Transplants in Advanced Parkinson's Disease: Clinical Outcomes," <i>Neurology</i> , 52:A405 (1999).	
	C13	Heiser <i>et al.</i> , "Inhibition of Huntingtin Fibrillogenesis by Specific Antibodies and Small Molecules: Implications for Huntington's Disease Therapy," <i>Proc. Natl. Acad. Sci. USA</i> , 97:6739-6744 (2000).	
	C14	Kopyov <i>et al.</i> , "Safety of Intrastratial Neurotransplantation for Huntington's Disease Patients," <i>Exp. Neurol.</i> , 149:97-108 (1998).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	March 30, 2004
				First Named Inventor	John McMichael
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	3	of	3	Attorney Docket Number	13024/38628A

C15	Kordower <i>et al.</i> , "Intravenous Administration of a Transferrin Receptor Antibody-nerve Growth Factor Conjugate Prevents the Degeneration of Cholinergic Striatal Neurons in a Model of Huntington Disease," <i>Proc. Natl. Acad. Sci. USA</i> , 91:9077-9080 (1994).	
C16	Lecerf <i>et al.</i> , "Human Single-chain Fv Intrabodies Counteract <i>in situ</i> Huntingtin Aggregation in Cellular Models of Huntington's Disease," <i>Proc. Natl. Acad. Sci. USA</i> , 98:4764-4769 (2001).	
C17	Martin <i>et al.</i> , "Regulatory Properties of Brain Glutamate Decarboxylase (GAD): The Apoenzyme of GAD is Present Principally as the Smaller of Two Molecular Forms of GAD in Brain," <i>J. Neuroscience</i> , 11:2725-2731 (1991).	
C18	Namchuck <i>et al.</i> , "Phosphorylation of Serine Residues 3, 6, 10, and 13 Distinguishes Membrane Anchored from Soluble Glutamic Acid Decarboxylase 65 and is Restricted to Glutamic Acid Decarboxylase 65 α^* ," <i>J. Biol. Chem.</i> , 272:1548-1557 (1997).	
C19	Peltola <i>et al.</i> , "No Evidence for Measles, Mumps, and Rubella Vaccine-Associated Inflammatory Bowel Disease or Autism in a 14-Year Prospective Study," <i>Lancet</i> , 351:1327-1328 (1998).	
C20	Porter <i>et al.</i> , "Transaminations Catalysed by Brain Glutamate Decarboxylase," <i>Biochem J.</i> , 231:705-712 (1985).	
C21	Qu <i>et al.</i> , "Motifs and Structural Fold of the Cofactor Binding Site of Human Glutamate Decarboxylase," <i>Protein Science</i> , 7:1092-1105 (1998).	
C22	Comi <i>et al.</i> , "Familial Clustering of Autoimmune Disorders and Evaluation of Medical Risk Factors in Autism," <i>J. of Child Neurology</i> , 14:388-394 (1999).	
C23	Wakefield <i>et al.</i> , "Ileal-lymphoid-nodular Hyperplasia, Non-specific Colitis, and Pervasive Developmental Disorder in Children," <i>Lancet</i> , 351:637-641 (1998).	
C24	Walker-Smith <i>et al.</i> , "Alpha-1-Antitrypsin, Autism, and Coeliac Disease," <i>Lancet</i> , ii:883-884 (1972).	
C25	D'Eufemia <i>et al.</i> , "Abnormal Intestinal Permeability in Children with Autism," <i>Acta Paediatrica</i> , 85:1076-1079 (1996).	
C26	Warren <i>et al.</i> , "Elevated Serotonin Levels in Autism: Association with the Major Histocompatibility Complex," <i>Neuropsychobiology</i> , 34:72-75 (1996).	
C27	Weiss, R.A., "Xenografts and Retroviruses," <i>Science</i> , 285:1221-1222(1999).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.